logo
logo
AI Products 

Ticagrelor An Antiplatelet Drug Is Fueling Growth Of The Global Ticagrelor Market

avatar
samruddhicmi12
Ticagrelor An Antiplatelet Drug Is Fueling Growth Of The Global Ticagrelor Market


The Global Ticagrelor Market is estimated to be valued at US$ 1285.83 Mn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


Market Overview:

Ticagrelor is an antiplatelet drug used to prevent blood clots. It inhibits platelet activation and aggregation helping to prevent strokes, heart attacks and other cardiovascular events. Ticagrelor provides more effective platelet inhibition as compared to clopidogrel making it superior for preventing atherothrombotic events in patients with acute coronary syndromes (ACS) or a history of myocardial infarction.


Market key trends:

One of the major driver for growth of ticagrelor market is increasing prevalence of cardiovascular diseases and approvals of ticagrelor drugs for new indications beyond ACS. According to World Health Organization, cardiovascular diseases are the leading cause of death globally, taking an estimate of over 17.9 million lives each year. Ticagrelor drugs has been approved for reducing the rate of cardiovascular events such as stroke or heart attack in patients with history of heart attack or peripheral artery disease. This expanded approval has positively impacted the adoption of ticagrelor drugs globally.



Segment Analysis

The global ticagrelor market is segmented by dosage, application, distribution channel, and region. By dosage, 60mg is the dominating segment as it is the approved dosage for treating acute coronary syndrome and other cardiovascular diseases. By application, the acute coronary syndrome segment dominates due to the rising prevalence of coronary artery disease. Geographically, North America holds the largest share in the ticagrelor market due to growing initiatives by healthcare organizations to spread awareness regarding antiplatelet treatment options.


Key Takeaways

The Global Ticagrelor Market Size is expected to witness high growth at a CAGR of 12% over the forecast period due to the increasing prevalence of cardiovascular diseases.


Regional analysis: North America dominates the ticagrelor market with a share of over 35% due to growing initiatives by healthcare organizations to spread awareness regarding antiplatelet treatment options. Asia Pacific is expected to grow at the fastest pace due to rising healthcare expenditure in countries like China and India.



Key players: Key players operating in the ticagrelor market are C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, Anhui Haikang Pharmaceutical Co., Ltd., Avra Laboratories Pvt. Ltd., and Sun Pharmaceutical Industries Ltd. AstraZeneca's Brilinta is the leading brand in the global ticagrelor market.


For more insights, read - https://www.marketwebjournal.com/ticagrelor-market-size

 



collect
0
avatar
samruddhicmi12
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more